Evidence map›Paper›PMID 42879017›Full record

ArticleMethods in molecular biology (Clifton, N.J.)2027

Application of Resazurin and ATP Detection Cell Viability Assays for Drug Sensitivity Screening in Ewing Sarcoma.

Annika Jeschke, Julian Musa, Florencia Cidre-Aranaz, Shunya Ohmura, Sheraz Gul

Abstract read
PubMed Publisher
In one paragraph

Article in Methods in molecular biology (Clifton, N.J.), 2027. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Annika JeschkeDivision of Translational Pediatric Sarcoma Research, German Cancer Research Center (DKFZ), Heidelberg, Germany.
Julian MusaDivision of Translational Pediatric Sarcoma Research, German Cancer Research Center (DKFZ), Heidelberg, Germany.
Florencia Cidre-AranazDivision of Translational Pediatric Sarcoma Research, German Cancer Research Center (DKFZ), Heidelberg, Germany. Florencia.cidrearanaz@dkfz-heidelberg.de.
Shunya OhmuraDivision of Translational Pediatric Sarcoma Research, German Cancer Research Center (DKFZ), Heidelberg, Germany.
Sheraz GulFraunhofer Institute for Translational Medicine and Pharmacology ITMP, Discovery Research ScreeningPort, Hamburg, Germany.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Developing new effective therapies for Ewing sarcoma (EwS) is crucial to improving patient outcomes, especially in cases of metastatic or recurrent disease. In various stages of drug discovery and especially early preclinical development, cell viability assays are often used to assess the antitumor efficacy of compounds of interest. Here, we review and provide guidelines for the application of resazurin- and ATP-based cell viability assays for drug sensitivity screening in EwS. This includes dose-response drug screening to identify metrics such as potency and to compare sensitivity across multiple cell lines, as well as high-throughput drug screening to identify hit compounds that inhibit EwS cells.

Indexed as

Adenosine TriphosphateAntineoplastic AgentsOxazinesSarcoma, EwingXanthenesCell Line, TumorCell SurvivalDrug Screening Assays, AntitumorHigh-Throughput Screening AssaysHumansAdenosine TriphosphateAntineoplastic AgentsOxazinesresazurinXanthenesCell viabilityDrug screeningEwing sarcomaFluorescenceLuminescence

Identifiers

PMID42879017

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.